Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases
Summary Thymosin alpha 1 (Tα1) is a powerful modulator of immunity and inflammation. Despite years of studies, there are a few reports evaluating serum Tα1 in health and disease. We studied a cohort of healthy individuals in comparison with patients affected by chronic inflammatory autoimmune diseas...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental immunology 2016-10, Vol.186 (1), p.39-45 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 45 |
|---|---|
| container_issue | 1 |
| container_start_page | 39 |
| container_title | Clinical and experimental immunology |
| container_volume | 186 |
| creator | Pica, F. Chimenti, M. S. Gaziano, R. Buè, C. Casalinuovo, I. A. Triggianese, P. Conigliaro, P. Di Carlo, D. Cordero, V. Adorno, G. Volpi, A. Perricone, R. Garaci, E. |
| description | Summary
Thymosin alpha 1 (Tα1) is a powerful modulator of immunity and inflammation. Despite years of studies, there are a few reports evaluating serum Tα1 in health and disease. We studied a cohort of healthy individuals in comparison with patients affected by chronic inflammatory autoimmune diseases. Sera from 120 blood donors (healthy controls, HC), 120 patients with psoriatic arthritis (PsA), 40 with rheumatoid arthritis (RA) and 40 with systemic lupus erythematosus (SLE), attending the Transfusion Medicine or the Rheumatology Clinic at the Policlinico Tor Vergata, Rome, Italy, were tested for Tα1 content by means of a commercial enzyme‐linked immunosorbent assay (ELISA) kit. Data were analysed in relation to demographic and clinical characteristics of patients and controls. A gender difference was found in the HC group, where females had lower serum Tα1 levels than males (P |
| doi_str_mv | 10.1111/cei.12833 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5011367</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1827899904</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4483-9f9f4e909c6b3d451db24eb473e76e2efd08f48581b703400063a826f0579d7e3</originalsourceid><addsrcrecordid>eNqNkc1O3DAURq2qiBmmLPoClZdlEfBfYntTqRoBRUJiAV1bTnLTcRXHUzsBzWPxIjwThpmO2gUS3lhX9-josz-EPlNySvM5a8CdUqY4_4DmlFdlwZjQH9GcEKILTYmYoaOUfuexqip2iGZM8pIQpebo7hbi5PG42viQ3ICfHjHFPdxDn3Ae13Z0MIwJP7hxhZtVDINr8qLrrfd2DHGD7TQG5_00AG5dApsgfUIHne0THO_uBfp5cX63_FFc31xeLb9fF40Qihe6050ATXRT1bwVJW1rJqAWkoOsgEHXEtUJVSpaS8LFS3xuFas6UkrdSuAL9G3rXU-1h7bJSaPtzTo6b-PGBOvM_5vBrcyvcG9KQvM_ySz4uhPE8GeCNBrvUgN9bwcIUzJUMam01kS8A6WSCKorktGTLdrEkFKEbp-IEvNSmMmFmdfCMvvl3yfsyb8NZeBsCzy4HjZvm8zy_GqrfAbB1KDh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1817041960</pqid></control><display><type>article</type><title>Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Pica, F. ; Chimenti, M. S. ; Gaziano, R. ; Buè, C. ; Casalinuovo, I. A. ; Triggianese, P. ; Conigliaro, P. ; Di Carlo, D. ; Cordero, V. ; Adorno, G. ; Volpi, A. ; Perricone, R. ; Garaci, E.</creator><creatorcontrib>Pica, F. ; Chimenti, M. S. ; Gaziano, R. ; Buè, C. ; Casalinuovo, I. A. ; Triggianese, P. ; Conigliaro, P. ; Di Carlo, D. ; Cordero, V. ; Adorno, G. ; Volpi, A. ; Perricone, R. ; Garaci, E.</creatorcontrib><description>Summary
Thymosin alpha 1 (Tα1) is a powerful modulator of immunity and inflammation. Despite years of studies, there are a few reports evaluating serum Tα1 in health and disease. We studied a cohort of healthy individuals in comparison with patients affected by chronic inflammatory autoimmune diseases. Sera from 120 blood donors (healthy controls, HC), 120 patients with psoriatic arthritis (PsA), 40 with rheumatoid arthritis (RA) and 40 with systemic lupus erythematosus (SLE), attending the Transfusion Medicine or the Rheumatology Clinic at the Policlinico Tor Vergata, Rome, Italy, were tested for Tα1 content by means of a commercial enzyme‐linked immunosorbent assay (ELISA) kit. Data were analysed in relation to demographic and clinical characteristics of patients and controls. A gender difference was found in the HC group, where females had lower serum Tα1 levels than males (P < 0·0001). Patients had lower serum Tα1 levels than HC (P < 0·0001), the lowest were observed in PsA group (P < 0·0001 versus all the other groups). Among all patients, those who at the time of blood collection were taking disease‐modifying anti‐rheumatic drugs (DMARD) plus steroids had significantly higher Tα1 levels than those taking DMARD alone (P = 0·044) or no treatment (P < 0·0001), but not of those taking steroids alone (P = 0·280). However, whichever type of treatment was taken by the patients, serum Tα1 was still significantly lower than in HC and there was no treatment‐related difference in PsA group. Further prospective studies are necessary to confirm and deepen these observations. They might improve our understanding on the regulatory role of Tα1 in health and disease and increase our knowledge of the pathogenesis of chronic inflammatory autoimmune diseases.
Thymosin α1 (Tα1) is a powerful regulator of immunity and inflammation. Herein is reported that: (i) healthy female individuals have lower serum Tα1 than the male ones; (ii) patients with chronic inflammatory autoimmune diseases have lower serum Tα1 levels than healthy controls, the lowest are observed in Psoriatic arthritis (PsA); (iii) there is positive relation between anti‐rheumatic drugs and serum Tα1 in the total group of patients but not in PsA group. There is a need of more information on the complex interplay between different cell subsets in chronic inflammatory autoimmune diseases, also in relation to the Tα1 circulating levels.</description><identifier>ISSN: 0009-9104</identifier><identifier>EISSN: 1365-2249</identifier><identifier>DOI: 10.1111/cei.12833</identifier><identifier>PMID: 27350088</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Adult ; Aged ; autoimmune diseases ; Autoimmune Diseases - blood ; Autoimmune Diseases - diagnosis ; Autoimmune Diseases - drug therapy ; Biomarkers ; Case-Control Studies ; Chronic Disease ; Female ; Humans ; Inflammation - blood ; Inflammation - diagnosis ; Inflammation - drug therapy ; Male ; Middle Aged ; Original ; psoriatic arthritis ; Retrospective Studies ; rheumatoid arthritis ; Severity of Illness Index ; systemic lupus erythematosus ; Thymosin - analogs & derivatives ; Thymosin - blood ; thymosin α1 ; Treatment Outcome ; Young Adult</subject><ispartof>Clinical and experimental immunology, 2016-10, Vol.186 (1), p.39-45</ispartof><rights>2016 British Society for Immunology</rights><rights>2016 British Society for Immunology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4483-9f9f4e909c6b3d451db24eb473e76e2efd08f48581b703400063a826f0579d7e3</citedby><cites>FETCH-LOGICAL-c4483-9f9f4e909c6b3d451db24eb473e76e2efd08f48581b703400063a826f0579d7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011367/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011367/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27350088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pica, F.</creatorcontrib><creatorcontrib>Chimenti, M. S.</creatorcontrib><creatorcontrib>Gaziano, R.</creatorcontrib><creatorcontrib>Buè, C.</creatorcontrib><creatorcontrib>Casalinuovo, I. A.</creatorcontrib><creatorcontrib>Triggianese, P.</creatorcontrib><creatorcontrib>Conigliaro, P.</creatorcontrib><creatorcontrib>Di Carlo, D.</creatorcontrib><creatorcontrib>Cordero, V.</creatorcontrib><creatorcontrib>Adorno, G.</creatorcontrib><creatorcontrib>Volpi, A.</creatorcontrib><creatorcontrib>Perricone, R.</creatorcontrib><creatorcontrib>Garaci, E.</creatorcontrib><title>Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases</title><title>Clinical and experimental immunology</title><addtitle>Clin Exp Immunol</addtitle><description>Summary
Thymosin alpha 1 (Tα1) is a powerful modulator of immunity and inflammation. Despite years of studies, there are a few reports evaluating serum Tα1 in health and disease. We studied a cohort of healthy individuals in comparison with patients affected by chronic inflammatory autoimmune diseases. Sera from 120 blood donors (healthy controls, HC), 120 patients with psoriatic arthritis (PsA), 40 with rheumatoid arthritis (RA) and 40 with systemic lupus erythematosus (SLE), attending the Transfusion Medicine or the Rheumatology Clinic at the Policlinico Tor Vergata, Rome, Italy, were tested for Tα1 content by means of a commercial enzyme‐linked immunosorbent assay (ELISA) kit. Data were analysed in relation to demographic and clinical characteristics of patients and controls. A gender difference was found in the HC group, where females had lower serum Tα1 levels than males (P < 0·0001). Patients had lower serum Tα1 levels than HC (P < 0·0001), the lowest were observed in PsA group (P < 0·0001 versus all the other groups). Among all patients, those who at the time of blood collection were taking disease‐modifying anti‐rheumatic drugs (DMARD) plus steroids had significantly higher Tα1 levels than those taking DMARD alone (P = 0·044) or no treatment (P < 0·0001), but not of those taking steroids alone (P = 0·280). However, whichever type of treatment was taken by the patients, serum Tα1 was still significantly lower than in HC and there was no treatment‐related difference in PsA group. Further prospective studies are necessary to confirm and deepen these observations. They might improve our understanding on the regulatory role of Tα1 in health and disease and increase our knowledge of the pathogenesis of chronic inflammatory autoimmune diseases.
Thymosin α1 (Tα1) is a powerful regulator of immunity and inflammation. Herein is reported that: (i) healthy female individuals have lower serum Tα1 than the male ones; (ii) patients with chronic inflammatory autoimmune diseases have lower serum Tα1 levels than healthy controls, the lowest are observed in Psoriatic arthritis (PsA); (iii) there is positive relation between anti‐rheumatic drugs and serum Tα1 in the total group of patients but not in PsA group. There is a need of more information on the complex interplay between different cell subsets in chronic inflammatory autoimmune diseases, also in relation to the Tα1 circulating levels.</description><subject>Adult</subject><subject>Aged</subject><subject>autoimmune diseases</subject><subject>Autoimmune Diseases - blood</subject><subject>Autoimmune Diseases - diagnosis</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Biomarkers</subject><subject>Case-Control Studies</subject><subject>Chronic Disease</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammation - blood</subject><subject>Inflammation - diagnosis</subject><subject>Inflammation - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original</subject><subject>psoriatic arthritis</subject><subject>Retrospective Studies</subject><subject>rheumatoid arthritis</subject><subject>Severity of Illness Index</subject><subject>systemic lupus erythematosus</subject><subject>Thymosin - analogs & derivatives</subject><subject>Thymosin - blood</subject><subject>thymosin α1</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0009-9104</issn><issn>1365-2249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1O3DAURq2qiBmmLPoClZdlEfBfYntTqRoBRUJiAV1bTnLTcRXHUzsBzWPxIjwThpmO2gUS3lhX9-josz-EPlNySvM5a8CdUqY4_4DmlFdlwZjQH9GcEKILTYmYoaOUfuexqip2iGZM8pIQpebo7hbi5PG42viQ3ICfHjHFPdxDn3Ae13Z0MIwJP7hxhZtVDINr8qLrrfd2DHGD7TQG5_00AG5dApsgfUIHne0THO_uBfp5cX63_FFc31xeLb9fF40Qihe6050ATXRT1bwVJW1rJqAWkoOsgEHXEtUJVSpaS8LFS3xuFas6UkrdSuAL9G3rXU-1h7bJSaPtzTo6b-PGBOvM_5vBrcyvcG9KQvM_ySz4uhPE8GeCNBrvUgN9bwcIUzJUMam01kS8A6WSCKorktGTLdrEkFKEbp-IEvNSmMmFmdfCMvvl3yfsyb8NZeBsCzy4HjZvm8zy_GqrfAbB1KDh</recordid><startdate>201610</startdate><enddate>201610</enddate><creator>Pica, F.</creator><creator>Chimenti, M. S.</creator><creator>Gaziano, R.</creator><creator>Buè, C.</creator><creator>Casalinuovo, I. A.</creator><creator>Triggianese, P.</creator><creator>Conigliaro, P.</creator><creator>Di Carlo, D.</creator><creator>Cordero, V.</creator><creator>Adorno, G.</creator><creator>Volpi, A.</creator><creator>Perricone, R.</creator><creator>Garaci, E.</creator><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>201610</creationdate><title>Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases</title><author>Pica, F. ; Chimenti, M. S. ; Gaziano, R. ; Buè, C. ; Casalinuovo, I. A. ; Triggianese, P. ; Conigliaro, P. ; Di Carlo, D. ; Cordero, V. ; Adorno, G. ; Volpi, A. ; Perricone, R. ; Garaci, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4483-9f9f4e909c6b3d451db24eb473e76e2efd08f48581b703400063a826f0579d7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>autoimmune diseases</topic><topic>Autoimmune Diseases - blood</topic><topic>Autoimmune Diseases - diagnosis</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Biomarkers</topic><topic>Case-Control Studies</topic><topic>Chronic Disease</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammation - blood</topic><topic>Inflammation - diagnosis</topic><topic>Inflammation - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original</topic><topic>psoriatic arthritis</topic><topic>Retrospective Studies</topic><topic>rheumatoid arthritis</topic><topic>Severity of Illness Index</topic><topic>systemic lupus erythematosus</topic><topic>Thymosin - analogs & derivatives</topic><topic>Thymosin - blood</topic><topic>thymosin α1</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pica, F.</creatorcontrib><creatorcontrib>Chimenti, M. S.</creatorcontrib><creatorcontrib>Gaziano, R.</creatorcontrib><creatorcontrib>Buè, C.</creatorcontrib><creatorcontrib>Casalinuovo, I. A.</creatorcontrib><creatorcontrib>Triggianese, P.</creatorcontrib><creatorcontrib>Conigliaro, P.</creatorcontrib><creatorcontrib>Di Carlo, D.</creatorcontrib><creatorcontrib>Cordero, V.</creatorcontrib><creatorcontrib>Adorno, G.</creatorcontrib><creatorcontrib>Volpi, A.</creatorcontrib><creatorcontrib>Perricone, R.</creatorcontrib><creatorcontrib>Garaci, E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pica, F.</au><au>Chimenti, M. S.</au><au>Gaziano, R.</au><au>Buè, C.</au><au>Casalinuovo, I. A.</au><au>Triggianese, P.</au><au>Conigliaro, P.</au><au>Di Carlo, D.</au><au>Cordero, V.</au><au>Adorno, G.</au><au>Volpi, A.</au><au>Perricone, R.</au><au>Garaci, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases</atitle><jtitle>Clinical and experimental immunology</jtitle><addtitle>Clin Exp Immunol</addtitle><date>2016-10</date><risdate>2016</risdate><volume>186</volume><issue>1</issue><spage>39</spage><epage>45</epage><pages>39-45</pages><issn>0009-9104</issn><eissn>1365-2249</eissn><abstract>Summary
Thymosin alpha 1 (Tα1) is a powerful modulator of immunity and inflammation. Despite years of studies, there are a few reports evaluating serum Tα1 in health and disease. We studied a cohort of healthy individuals in comparison with patients affected by chronic inflammatory autoimmune diseases. Sera from 120 blood donors (healthy controls, HC), 120 patients with psoriatic arthritis (PsA), 40 with rheumatoid arthritis (RA) and 40 with systemic lupus erythematosus (SLE), attending the Transfusion Medicine or the Rheumatology Clinic at the Policlinico Tor Vergata, Rome, Italy, were tested for Tα1 content by means of a commercial enzyme‐linked immunosorbent assay (ELISA) kit. Data were analysed in relation to demographic and clinical characteristics of patients and controls. A gender difference was found in the HC group, where females had lower serum Tα1 levels than males (P < 0·0001). Patients had lower serum Tα1 levels than HC (P < 0·0001), the lowest were observed in PsA group (P < 0·0001 versus all the other groups). Among all patients, those who at the time of blood collection were taking disease‐modifying anti‐rheumatic drugs (DMARD) plus steroids had significantly higher Tα1 levels than those taking DMARD alone (P = 0·044) or no treatment (P < 0·0001), but not of those taking steroids alone (P = 0·280). However, whichever type of treatment was taken by the patients, serum Tα1 was still significantly lower than in HC and there was no treatment‐related difference in PsA group. Further prospective studies are necessary to confirm and deepen these observations. They might improve our understanding on the regulatory role of Tα1 in health and disease and increase our knowledge of the pathogenesis of chronic inflammatory autoimmune diseases.
Thymosin α1 (Tα1) is a powerful regulator of immunity and inflammation. Herein is reported that: (i) healthy female individuals have lower serum Tα1 than the male ones; (ii) patients with chronic inflammatory autoimmune diseases have lower serum Tα1 levels than healthy controls, the lowest are observed in Psoriatic arthritis (PsA); (iii) there is positive relation between anti‐rheumatic drugs and serum Tα1 in the total group of patients but not in PsA group. There is a need of more information on the complex interplay between different cell subsets in chronic inflammatory autoimmune diseases, also in relation to the Tα1 circulating levels.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>27350088</pmid><doi>10.1111/cei.12833</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9104 |
| ispartof | Clinical and experimental immunology, 2016-10, Vol.186 (1), p.39-45 |
| issn | 0009-9104 1365-2249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5011367 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Aged autoimmune diseases Autoimmune Diseases - blood Autoimmune Diseases - diagnosis Autoimmune Diseases - drug therapy Biomarkers Case-Control Studies Chronic Disease Female Humans Inflammation - blood Inflammation - diagnosis Inflammation - drug therapy Male Middle Aged Original psoriatic arthritis Retrospective Studies rheumatoid arthritis Severity of Illness Index systemic lupus erythematosus Thymosin - analogs & derivatives Thymosin - blood thymosin α1 Treatment Outcome Young Adult |
| title | Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A35%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20thymosin%20%CE%B1%201%20levels%20in%20patients%20with%20chronic%20inflammatory%20autoimmune%20diseases&rft.jtitle=Clinical%20and%20experimental%20immunology&rft.au=Pica,%20F.&rft.date=2016-10&rft.volume=186&rft.issue=1&rft.spage=39&rft.epage=45&rft.pages=39-45&rft.issn=0009-9104&rft.eissn=1365-2249&rft_id=info:doi/10.1111/cei.12833&rft_dat=%3Cproquest_pubme%3E1827899904%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1817041960&rft_id=info:pmid/27350088&rfr_iscdi=true |